Nighthawk

NETGEAR® Reports Third Quarter 2023 Results

Retrieved on: 
Wednesday, October 25, 2023

Third quarter 2023 net revenue of $197.8 million, a decrease of 20.7% from the comparable prior-year quarter.

Key Points: 
  • Third quarter 2023 net revenue of $197.8 million, a decrease of 20.7% from the comparable prior-year quarter.
  • Third quarter 2023 non-GAAP operating income of $5.3 million, or 2.7% of net revenue, as compared to operating income of $1.8 million, or 0.7% of net revenue, in the comparable prior-year quarter.
  • Third quarter 2023 GAAP net loss per diluted share of $2.87, as compared to net income per diluted share of $0.10 in the comparable prior-year quarter.
  • Third quarter 2023 non-GAAP net income per diluted share of $0.23, as compared to net income per diluted share of $0.21 in the comparable prior-year quarter.

NightHawk Biosciences Provides Q2 2023 Business Update

Retrieved on: 
Monday, August 14, 2023

Jeff Wolf, Chief Executive Officer of NightHawk, commented, “Development of our biomanufacturing operations, continues to progress.

Key Points: 
  • Jeff Wolf, Chief Executive Officer of NightHawk, commented, “Development of our biomanufacturing operations, continues to progress.
  • We look forward to providing updates on these programs.”
    For the three months ended June 30, 2023 we recognized $0.7 million of revenue from process development.
  • As of June 30, 2023, the Company had approximately $18.6 million in cash, cash equivalents, and short-term investments.
  • NightHawk Biosciences is focused on the discovery and commercialization of innovative medical countermeasures to defend against emerging biothreats.

NightHawk Biosciences Provides Q1 2023 Business Update

Retrieved on: 
Monday, May 15, 2023

For the three months ended March 31, 2022 we recognized $0.2 million of grant revenue for qualified expenditures under the CPRIT grant.

Key Points: 
  • For the three months ended March 31, 2022 we recognized $0.2 million of grant revenue for qualified expenditures under the CPRIT grant.
  • As of March 31, 2023, we had a grants receivable balance of $1.5 million for the final CPRIT tranche, and received those funds in April 2023. .
  • Selling, general and administrative expenses were $6.8 million and $3.8 million for the three months ended March 31, 2023 and 2022, respectively.
  • As of March 31, 2023, the Company had approximately $28.6 million in cash, cash equivalents, and short-term investments.

NETGEAR® Reports First Quarter 2023 Results

Retrieved on: 
Wednesday, April 26, 2023

First quarter 2023 net revenue of $180.9 million, a decrease of 14.1% from the comparable prior-year quarter.

Key Points: 
  • First quarter 2023 net revenue of $180.9 million, a decrease of 14.1% from the comparable prior-year quarter.
  • First quarter 2023 non-GAAP operating loss of $7.1 million, or (3.9)% of net revenue, as compared to operating loss of $9.3 million, or (4.4)% of net revenue, in the comparable prior-year quarter.
  • First quarter 2023 GAAP net loss per diluted share of $0.33, as compared to net loss per diluted share of $1.95 in the comparable prior-year quarter.
  • First quarter 2023 non-GAAP net loss per diluted share of $0.19, as compared to net loss per diluted share of $0.28 in the comparable prior-year quarter.

Nighthawk Gold’s Maiden PEA: C$1.2 Billion NPV5% and 35% IRR after-taxes at US$1,600/oz Gold

Retrieved on: 
Wednesday, April 26, 2023

We strongly believe that this Project PEA is the cornerstone of what could be a major gold camp.”

Key Points: 
  • We strongly believe that this Project PEA is the cornerstone of what could be a major gold camp.”
    “We have an exciting rest of the year ahead of us.
  • In the near term, we are expecting assay results from the highly prospective Leta Arm Zone.
  • Construction is managed by EPCM then transitioned to owner-operator upon commencement of initial gold production.
  • The average estimated gold recovery is 96.3%, which is supported by the metallurgical testing5 completed by the Company.

NightHawk Biosciences Provides 2022 Year End Business Update

Retrieved on: 
Friday, March 31, 2023

For the year ended December 31, 2021, the Company recognized revenue of $2.1 million for qualified expenditures under the CPRIT grant.

Key Points: 
  • For the year ended December 31, 2021, the Company recognized revenue of $2.1 million for qualified expenditures under the CPRIT grant.
  • Selling, general and administrative (“SGA”) expenses for the years ended December 31, 2022 and 2021 were $21.1 million and $16.8 million, respectively.
  • Research and development expenses increased to $23.5 million from $16.5 million for the years ended December 31, 2022 and 2021, respectively.
  • As of December 31, 2022, the Company had approximately $44.3 million in cash, cash equivalents, and short-term investments.

NETGEAR Introduces the First WiFi 7 Router, Unlocking the Next Generation of High-Performance Connectivity

Retrieved on: 
Tuesday, March 14, 2023

Built by an experienced team with 25+ years of pioneering WiFi expertise, the NETGEAR Nighthawk RS700 Router is spearheading the WiFi 7 revolution.

Key Points: 
  • Built by an experienced team with 25+ years of pioneering WiFi expertise, the NETGEAR Nighthawk RS700 Router is spearheading the WiFi 7 revolution.
  • View the full release here: https://www.businesswire.com/news/home/20230314005398/en/
    NETGEAR introduces Nighthawk RS700, the first WiFi 7 router with powerful new antenna design, sleek ID and up to 19Gbps of blazing fast WiFi.
  • (Photo: Business Wire)
    The WiFi requirements of modern, hyper-connected homes continue to push the boundaries of today’s WiFi standards.
  • While WiFi 6E opened the 6GHz band as a superhighway for the latest, fastest devices, WiFi 7 makes good on that promise by unleashing unprecedented speeds and performance.

Nighthawk Gold Updated Mineral Resource Estimate Demonstrates Significant Boost to the Global and Open-Pit Mineral Resources

Retrieved on: 
Thursday, February 9, 2023

commented: “Our 2023 MRE demonstrates a significant boost in estimated ounces in the Indicated and Inferred categories compared to last year.

Key Points: 
  • commented: “Our 2023 MRE demonstrates a significant boost in estimated ounces in the Indicated and Inferred categories compared to last year.
  • More importantly, the OP mineralization has reached 2.8 million estimated ounces in the Indicated category and 0.8 million ounces in the Inferred category.
  • We believe there is a massive potential for discovering more gold mineralization across our 930 km2 district-scale property.
  • Please refer to “Notes to Accompany the 2023 MRE” at the end of the news release for more information on the parameters and assumptions.

Americana Songstress Emma Jo To Release Powerful New Single, 'Straight Into Mine'

Retrieved on: 
Tuesday, February 7, 2023

NASHVILLE, Tenn., Feb. 6, 2023 /PRNewswire/ -- Like the mighty phoenix that rises from the ashes reborn and more alive than ever before, a refreshed Emma Jo is finally living her happily ever after. Now divorced, the singer is set to release on March 31 her upcoming single, "Straight into Mine," an intimate tune filled with raw, honest emotion chronicling her journey toward personal growth and liberation.

Key Points: 
  • "In the song, I'm reflecting on a relationship—actually a MARRIAGE—where I couldn't be my true self," she explains.
  • "With my ex, I couldn't go out, wear makeup or heels, or do things on my own.
  • A slight detour from her normal sound, "Straight into Mine" exudes the feel of mainstream country with Emma Jo's powerful truth and vulnerability taking center stage.
  • In addition to being a talented singer/songwriter, amid her divorce, Emma Jo became a certified life coach to help others.

DuPont to Highlight Healthcare Portfolio, Medical Device Partnerships at MD&M West

Retrieved on: 
Thursday, February 2, 2023

WILMINGTON, Del., Feb. 2, 2023 /PRNewswire-PRWeb/ -- DuPont (NYSE:DD) today announced that it will highlight DuPont™ Liveo™ Healthcare Solutions – with an emphasis on the brand's medical device product lines – at MD&M West 2023, which will take place Feb. 7-9 in Anaheim, California.

Key Points: 
  • Customers will see expanding product line, opportunities for collaboration
    WILMINGTON, Del., Feb. 2, 2023 /PRNewswire-PRWeb/ -- DuPont (NYSE:DD) today announced that it will highlight DuPont™ Liveo™ Healthcare Solutions – with an emphasis on the brand's medical device product lines – at MD&M West 2023 , which will take place Feb. 7-9 in Anaheim, California.
  • "From concepting to commercialization, we support an ecosystem of medical device partners and work with them to create smarter next-generation devices," said Liveo™ Healthcare Solutions Americas Marketing Leader Diana Salvadori.
  • "Whether customers are looking for technological expertise; regulatory support; or a broad selection of high-quality, medical-grade materials that are easy to process and patient-friendly, DuPont serves a broad spectrum of medical device applications."
  • Over the last 70-plus years, DuPont – a trusted partner in the medical device industry – has developed a leadership position within the industry by building upon foundational capabilities that serve the highly regulated healthcare market.